AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17197857
Drug: Bupivacaine (3.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine (3.3 mg ED95) combined with 1.5 microg sufentanil
Trial: 17197857
Drug: Ropivacaine (4.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine (4.8 mg ED95) combined with 1.5 microg sufentanil
Trial: 17197857
Drug: Levobupivacaine (5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levobupivacaine (5.0 mg ED95) combined with 1.5 microg sufentanil
Trial: 12173010
Drug: CPT MBF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT MBF corrected by RPP in smokers (0.65 ± 0.12 ml g(‐1) min(‐1))
Trial: 12173010
Drug: Rest MBF
RxNorm normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rest MBF in smokers (0.86 ± 0.11 ml g(‐1) min(‐1))
Trial: 12173010
Drug: Hyperaemic MBF
RxNorm normalized name: 1-36 human humoral hypercalcemic factor
DrugBank: Parathyroid Hormone-Related Protein 1-36 (DB16278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperaemic MBF during ATP infusion in smokers (3.20 ± 1.12 ml g(‐1) min(‐1))
Trial: 8553632
Drug: Zontac (histamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zontac (histamine H2-receptor blocking agent) administered intravenously 50 mg thrice a day for 3 days, then orally 150 mg twice a day for 3 weeks
Trial: 30925074
Drug: Intensive dysarthria
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive dysarthria therapy (three 40-minute sessions per week for six weeks)
Trial: 26013051
Drug: High intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intensity interval training (HIIT) at 85‐95% of HRmax, performed twice a week for 10 weeks on spinning bikes.
Trial: 25411597
Drug: Ipragliflozin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipragliflozin (all doses)
Trial: 21752511
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine with 0.125 mg/mL epinephrine
Trial: 21752511
Drug: 4% articaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% articaine with 0.006 mg/mL epinephrine
Trial: 21752511
Drug: 4% articaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% articaine with 0.012 mg/mL epinephrine
Trial: 16764623
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (n = 52)
Trial: 15385832
Drug: Everolimus starting
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus starting dose of 0.75 mg bid (n = 112)
Trial: 15385832
Drug: Everolimus starting
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus starting dose of 1.5 mg bid (n = 125)
Trial: 15385832
Drug: Cyclosporine dosing
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine dosing
Trial: 15385832
Drug: Everolimus C0
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus C0 between 3 and 8 ng/mL
Trial: 7658304
Drug: 0.25% itraconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% itraconazole cream
Trial: 7658304
Drug: 0.50% itraconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.50% itraconazole cream
Trial: 18090696
Drug: Propofol (120.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (120.9 +/- 50.0 mg)
Trial: 18090696
Drug: Methohexital (83
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methohexital (83 +/- 26.3 mg)
Trial: 16275379
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy with standardized hazelnut extract
Trial: 15833834
Drug: Letrozole therapy
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole therapy for 1 month
Trial: 15833834
Drug: Letrozole therapy
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole therapy for 3 months
Trial: 9884249
Drug: C2 (700-1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C2 (700-1000 ng/ml)
Trial: 9884249
Drug: C0 (100-200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C0 (100-200 ng/ml)
Trial: 9884249
Drug: C2 (300-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C2 (300-600 ng/ml)
Trial: 8571773
Drug: Continuous transdermal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous transdermal blanket suture using nonabsorbable material (silk)
Trial: 1535202
Drug: Propofol anesthesia
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol anesthesia (2.5 mg/kg)
Trial: 1535202
Drug: Thiamylal-enflurane anesthesia
RxNorm normalized name: thiamylal
DrugBank: Thiamylal (DB01154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiamylal-enflurane anesthesia (4 mg/kg)
Trial: 6498579
Drug: Propranolol 0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 0.01 mg X kg‐1 IV, administered two minutes prior to induction
Trial: 6498579
Drug: Propranolol 0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 0.01 mg X kg‐1 IV, administered five minutes prior to induction
Trial: 6498579
Drug: Propranolol 0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol 0.01 mg X kg‐1 IV, administered eight minutes prior to induction
Trial: 6498579
Drug: Saline pretreatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline pretreatment, administered five minutes prior to induction
Trial: 25936814
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (total dose of 6.0 Gy applied in 6 fractions of 1.0 Gy three times a week)
Trial: 25936814
Drug: Local corticosteroid
RxNorm normalized name: Corticosteroids acting locally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local corticosteroid injections (1 ml injection of 40 mg methylprednisolone and 0.5 ml 1% lidocaine under the guidance of palpation)
Trial: 23566060
Drug: Flaxseed supplementation
RxNorm normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed supplementation (30 g/day) for 30 days
Trial: 16491348
Drug: Gastrografin (350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastrografin (350 ml) of three different concentrations
Trial: 14684757
Drug: Supplemental vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental vitamin C (approximately 70 mg/day)
Trial: 9233735
Drug: rhIL‐1ra (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIL‐1ra (100 mg) followed by a 72‐hr continuous intravenous infusion of rhIL‐1ra (2.0 mg/kg/hr)
Trial: 9233735
Drug: Placebo (vehicle)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (vehicle) followed by a 72‐hr continuous intravenous infusion of placebo
Trial: 8497364
Drug: Crossover to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover to metronidazole gel
Trial: 3305215
Drug: 18-month maintenance
RxNorm normalized name: cenobamate
DrugBank: Cenobamate (DB06119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 18-month maintenance therapy
Trial: 3305215
Drug: Intermediate-dose methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intermediate-dose methotrexate (IDMTX) plus intrathecal methotrexate
Trial: 29476019
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg fresolimumab
Trial: 29476019
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg fresolimumab
Trial: 29476019
Drug: Focal radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Focal radiotherapy (three doses of 7.5 Gy)
Trial: 26622051
Drug: Intramuscular testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular testosterone (250 mg) every 2 weeks for 24 weeks
Trial: 26622051
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 mL saline) every 2 weeks for 24 weeks
Trial: 16222197
Drug: Terbinafine 625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 625 mg/day (n = 25)
Trial: 10150266
Drug: MS Contin
RxNorm normalized name: MS Contin
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MS Contin 30 mg
Trial: 10150266
Drug: MS Contin
RxNorm normalized name: MS Contin
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MS Contin 60 mg
Trial: 10150266
Drug: Oramorph SR
RxNorm normalized name: Oramorph SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oramorph SR 60 mg
Trial: 3122699
Drug: Bupropion hydrochloride
RxNorm normalized name: Bupropion Hydrochloride
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion hydrochloride (dosage not specified)
Trial: 28590765
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (rest, NSAİİ, bracing, exercise)
Trial: 23163825
Drug: Losartan 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 200 mg/day
Trial: 20817148
Drug: Group Person-Based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Person-Based Cognitive Therapy (PBCT)
Trial: 16679299
Drug: Lercanidipine 10-20
RxNorm normalized name: lercanidipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lercanidipine 10-20 mg once daily
Trial: 16679299
Drug: Losartan 50-100
RxNorm normalized name: losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan 50-100 mg once daily
Trial: 15572814
Drug: Penicillin G
RxNorm normalized name: penicillin G
DrugBank: Benzylpenicillin (DB01053)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin G + Chloramphenicol (n:46)
Trial: 8215565
Drug: Early lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early lipid containing parenteral nutrition
Trial: 8215565
Drug: Late lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late lipid containing parenteral nutrition
Trial: 28985195
Drug: Dexamethasone (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.1 mg/kg IV bolus 10 hours before surgery)
Trial: 25765602
Drug: Constraint‐Induced Aphasia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint‐Induced Aphasia Therapy (CIAT)
Trial: 25765602
Drug: Semantic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semantic therapy (BOX)
Trial: 19204212
Drug: GP training
RxNorm normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP training plus cost-free nicotine replacement medication and/or bupropion hydrochloride
Trial: 19204212
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of GP training plus GP remuneration and cost-free nicotine replacement medication and/or bupropion hydrochloride
Trial: 17322142
Drug: Anidulafungin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anidulafungin (200 mg IV on day 4, followed by 100 mg IV on days 5-13)
Trial: 17322142
Drug: Tacrolimus (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus (5 mg orally on days 1 and 13)
Trial: 9806253
Drug: GnRHa (nafarelin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRHa (nafarelin acetate/Synarel) at a dosage of 200 microg three times daily until HCG administration
Trial: 9806253
Drug: GnRHa (nafarelin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRHa (nafarelin acetate/Synarel) reduced to 200 microg twice daily as ovarian stimulation was initiated
Trial: 3347522
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cephalocaudal stroking and multisensory hammock
Trial: 29795368
Drug: Plant sterols
RxNorm normalized name: Plant Sterols/Stanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant sterols (PS) 2 g/d
Trial: 18441530
Drug: Combined HB‐Hib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined HB‐Hib vaccine (Hebervac HB‐Hib)
Trial: 18441530
Drug: HB vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HB vaccine (Heberbiovac‐HB) and Hib vaccine (QuimiHib)
Trial: 16569462
Drug: Maintenance gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance gemcitabine (1,250 mg/m² on days 1 and 8 every 21 days) plus best supportive care (GEM arm)
Trial: 8737166
Drug: 250 g
RxNorm normalized name: WORMWOOD OIL 100 g in 250 g TOPICAL GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 g preload
Trial: 8737166
Drug: 500 g
RxNorm normalized name: PRAZIQUANTEL 500 g in 500 g POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 g preload
Trial: 8737166
Drug: 750 g
RxNorm normalized name: Isopropyl Alcohol 750 g in 1 kg TOPICAL SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 g preload
Trial: 1559192
Drug: Placebo (for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (for four weeks prior to quinapril therapy)
Trial: 3926036
Drug: Low residue
RxNorm normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low residue liquidized diet (Isocal) administered to treatment group
Trial: 3926036
Drug: Routine intravenous
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine intravenous therapy administered to control group
Trial: 31672256
Drug: Visco-ease™ oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visco-ease™ oral spray
Trial: 17323135
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K supplementation (500 microg daily)
Trial: 15334317
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate (Rb) 400 mg twice a day, tetracycline (T) 1 g twice a day, metronidazole (M) 500 mg three times a day for 14 days (RbTM)
Trial: 15334317
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate (Rb) 400 mg twice a day for 14 days and azithromycin (A) 500 mg once a day for 7 days (RbA)
Trial: 2666019
Drug: Cycloprovera (medroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycloprovera (medroxyprogesterone acetate 25 mg + estradiol cypionate 5 mg)
Trial: 2666019
Drug: HRP-102 (norethisterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRP-102 (norethisterone enanthate 50 mg + estradiol valerate 5 mg)
Trial: 140037
Drug: Minoxidil in
RxNorm normalized name: Product containing minoxidil in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minoxidil in combination with frusemide and propranolol
Trial: 140037
Drug: Hydrallazine in
RxNorm normalized name: Hydrallazine
DrugBank: Hydralazine (DB01275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrallazine in combination with frusemide and propranolol
Trial: 28409242
Drug: Topical ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ropivacaine with 20 mg ketamine (RK group)
Trial: 28409242
Drug: Topical ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ropivacaine with saline (RS group)
Trial: 20694567
Drug: Ultrasonic vibration
RxNorm normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasonic vibration (V) with G-Cem (GC)
Trial: 20694567
Drug: Static seating
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Static seating pressure (P) with G-Cem (GC)
Trial: 2406105
Drug: Active specific
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active specific immunotherapy using the patient's tumor cells to create a vaccine
Trial: 7413719
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg daily of cannabidiol (CBD) for 30 days in healthy volunteers
Trial: 7413719
Drug: 200-300 mg
RxNorm normalized name: allopurinol 300 MG / lesinurad 200 MG [Duzallo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200-300 mg daily of cannabidiol (CBD) for 4 1/2 months in epilepsy patients
Trial: 7413719
Drug: Placebo (glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (glucose capsules) for 30 days in healthy volunteers
Trial: 24028755
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of salbutamol (15 μg/kg IBW/hour)
Trial: 19660492
Drug: Extended-release morphine
RxNorm normalized name: morphine Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release morphine
Trial: 19660492
Drug: Hydrocodone plus
RxNorm normalized name: acetaminophen / hydrocodone Oral Capsule [Ceta Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocodone plus acetaminophen
Trial: 18261269
Drug: Adverse drug
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse drug reactions in Group A and B
Trial: 15089956
Drug: Implementation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implementation of an oral analgesic algorithm derived from systematic reviews
Trial: 11791961
Drug: Wheat germ
RxNorm normalized name: Wheat Germ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat germ (WG) 2 g, 3 times a day for 10 days
Trial: 11791961
Drug: Metronidazole (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (250 mg 3 times a day) plus WG
Trial: 11791961
Drug: Placebo (cornstarch,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (cornstarch, 2 g, 3 times a day)
Trial: 11791961
Drug: Metronidazole (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (250 mg 3 times a day) plus placebo
Trial: 8072199
Drug: CSF 39-300
RxNorm normalized name: rGM-CSF
DrugBank: Sargramostim (DB00020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CSF 39-300 (10 micrograms/kg daily via intravenous infusion for 21 days)
Trial: 28929861
Drug: Ulipristal Acetate
RxNorm normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ulipristal Acetate (10 mg/d)
Trial: 24923077
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg bevacizumab
Trial: 18640473
Drug: Metformin 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1.5 g/d (MET group)
Trial: 12844280
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (benzodiazepines and conventional antipsychotics)
Trial: 12844280
Drug: Atypical antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotics (ziprasidone, risperidone, olanzapine)
Trial: 28061907
Drug: GFF MDI
RxNorm normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFF MDI 72/9.6 μg BID
Trial: 28061907
Drug: GFF MDI
RxNorm normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFF MDI 36/9.6 μg BID
Trial: 28061907
Drug: Tiotropium DPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium DPI 18 μg once daily
Trial: 28061907
Drug: FF DPI
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: FF DPI 12 μg BID
Trial: 21437522
Drug: Topical combination
RxNorm normalized name: soap TOPICAL COMBINATION PACKAGE (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical combination of benzoyl peroxide 5% and clindamycin 1%
Trial: 21437522
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel cream
Trial: 19884606
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral analysis system of psychotherapy (CBASP) and continued pharmacotherapy (MEDS)
Trial: 19884606
Drug: Brief supportive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief supportive psychotherapy (BSP) and continued pharmacotherapy (MEDS)
Trial: 19884606
Drug: Continued optimized
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued optimized pharmacotherapy (MEDS) alone
Trial: 17301637
Drug: Smoking (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking (25 g/day or more)
Trial: 17301637
Drug: Increase in
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase in serum cholesterol of 1 mmol/l
Trial: 11141144
Drug: Lisinopril 10
RxNorm normalized name: lisinopril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 10 mg once daily for one week, then 20 mg once daily for 11 weeks